Aravind Palraj/X
Sep 19, 2026, 01:24
Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“2025 EULAR Behçet’s syndrome update — 5 practical take-home points:
- Colchicine remains first-line for recurrent mucocutaneous disease and acute arthritis
- Behçet uveitis needs immunosuppression — glucocorticoids should not be used alone
- Pulmonary or peripheral arterial aneurysm – high-dose glucocorticoids with infliximab; embolisation is preferred over open surgery when intervention is needed
- Venous thrombosis – control inflammation first; anticoagulation is not automatic and pulmonary artery aneurysm must be excluded
- Major organ disease increasingly favors early intensive immunosuppression, often with monoclonal anti-TNF therapy
A useful update across mucocutaneous, ocular, vascular, neurologic and GI Behçet’s disease.”
Other posts featuring Aravind Palraj on Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke